glp-1 news october 21 2025 ISPOR 2025: Exploring reasons for discontinuation GLP-1 Weight Loss Drug Enforcement

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially developed for the treatment of type 2 diabetes and obesity, may modulate pathways associated with the hallmarks of aging

We review how it works.

Obesity is a growing epidemic that affects millions of people worldwide, leading to serious health complications such as heart disease, diabetes, and certain cancers

While agreements to lower the prices of GLP-1s wont immediately affect employer-sponsored health plans, they could eventually bring down costs.

An Ohio State dietitian offers advice.

FDA-approved oral GLP-1s match injectables in weight loss effectiveness with similar side effects and health benefits